Elevance Health, Inc. (ELV) is a pioneering healthcare technology company that is focused on improving patient care outcomes and savings in the healthcare industry. The company is at the forefront of digital healthcare revolution, offering cutting-edge technology solutions by integrating advanced artificial intelligence (AI), machine learning (ML), and data analytics into its healthcare platforms.
Based in the United States, Elevance Health has built a strong reputation for driving innovation in the healthcare industry. The company’s mission is to streamline healthcare management, reduce healthcare costs, and improve patient outcomes through technology-driven solutions. By integrating AI and ML into their services, Elevance Health is efficiently addressing the prevalent issues of care coordination, patient engagement, and data interoperability in the healthcare industry.
Elevance Health’s primary product is an AI-powered patient engagement platform. It essentially serves as a collaborative tool between healthcare providers, patients, and their families. The platform empowers health providers with relevant data insights to make informed decisions in real-time, improving their ability to offer personalized and effective treatment plans. For patients and their families, the platform facilitates ease of access to medical records, education about their conditions, and constant communication with their healthcare providers. All of these features together pave the way for more effective home-based care.
In addition, Elevance Health’s data analytics capability is designed to provide a holistic view of a patient's health status. This insight can help healthcare providers identify potential health risks early on and intervene with preventive strategies. With a commitment towards data security, the company takes patient confidentiality seriously and ensures that all data processing is compliant with HIPAA privacy regulations.
Despite being a relatively new player in the healthcare technology space, Elevance Health has already garnered notable industry recognition for its novel approach to improving patient care. The innovative solutions offered by the company, combining AI with healthcare, is just the beginning of a new era in the medical field. They believe in continually evolving their services to better meet the needs of healthcare providers and patients.
Overall, Elevance Health plays a crucial role in redefining how healthcare providers and patients interact and how care is delivered. By continuously striving towards improving patient engagement and reducing healthcare costs, Elevance Health is positioning itself as a stalwart in the healthcare technology sector. As healthcare continues to evolve, Elevance Health is primed to be at the forefront of transformative changes, creating a positive impact on healthcare efficiency, cost, and patient satisfaction.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Morningstar identified 24 new 4-star stocks for the week ended October 30, indicating these stocks are now considered undervalued. Among the largest market capitalization companies to receive a 4-star rating are HSBC, Caterpillar, Banco Bilbao Vizcaya Argentaria, Elevance Health, and Ecolab. The Morningstar Rating helps investors find undervalued stocks by comparing their price to Morningstar's fair value estimate and considering an Uncertainty Rating.
Cardiac-monitoring company iRhythm Technologies disclosed a data breach that affected 8.2 million people after attackers accessed third-party-hosted business applications. The breach exposed personal, insurance, and device-related information, including names, addresses, dates of birth, and insurance numbers, though clinical and device systems were not affected. iRhythm detected the unauthorized access between June 3 and June 8, 2026, and later faced an extortion attempt.
Simplify Asset Management Inc. significantly reduced its stake in Elevance Health (NYSE:ELV) by 71.4% in the third quarter, selling 18,261 shares and retaining 7,316 shares worth approximately $2.85 million. This comes as Elevance Health reported strong quarterly earnings of $6.99 per share, exceeding analyst expectations, and a revenue of $50.44 billion. The company also declared a quarterly dividend of $1.72 per share, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $456.48.
DaVita Inc. (NYSE:DVA) is set to report earnings this Thursday. The company beat revenue expectations last quarter but missed full-year EPS guidance. Analysts generally anticipate revenue growth of 2.8% year-on-year for the upcoming quarter, and the stock is trading below its average analyst price target.
Axogen Inc. reported a 26.2% increase in Q3 2026 revenue to $75.8 million, driven by strong growth in all markets, particularly the breast segment which saw over 50% growth. The company also completed the acquisition of BioCircuit, integrating nerve tape into its product portfolio, and revised its full-year 2026 revenue guidance to at least $290 million. Additionally, Axogen announced plans to initiate prostate nerve reconstruction market development in 2027, citing positive clinical outcomes from early studies.
HCA Healthcare exceeded Wall Street expectations for its third-quarter results due to strong demand for medical services, despite an increase in uninsured patients impacting income. The company now anticipates its full-year 2026 financial performance to be in the upper half of its previously forecast range, with significant growth in admissions and revenue. This positive outlook comes despite federal policy changes that have led to more patients losing health insurance coverage.
HCA Healthcare exceeded Wall Street's third-quarter profit estimates due to strong demand for medical services, despite an increase in uninsured patients. The hospital operator's shares rose, and the company now expects its full-year 2026 financial results to be in the upper half of its previously forecast range. Revenue and admissions also increased, signaling a positive outlook for the company despite challenges from federal policy changes.
Labcorp Holdings (NYSE: LH), a healthcare diagnostics company, is set to report earnings this Wednesday. Analysts expect revenue growth of 5.6% year-on-year, a slowdown from the previous year, though estimates have been reconfirmed. The article notes Labcorp's past revenue misses and provides insights from peer performance in the healthcare sector.